Cure Rare Disease Acquires Laboratory Space for New Headquarters in Connecticut

September 29, 2022 |

2 min read

Cure Rare Disease, a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.

Boston-based biotechnology company to relocate headquarters and expand operations in Woodbridge

WOODBRIDGE, Conn.--(BUSINESS WIRE)-- Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005008/en/

Photo of 4 Research Drive facility (Photo: Business Wire)

The 30,000 square foot facility was purchased by CRD to continue its mission of developing therapeutics for rare and ultra-rare neuromuscular diseases through a novel framework. CRD will also make 15,000 square feet of space available for lease to other life science and healthcare firms.

“We are excited to join the Woodbridge and greater New Haven communities to deepen our R&D efforts for rare disease patients while also offering biotechnology companies the opportunity to access Class A life sciences space in the New Haven area,” said CRD Founder and CEO, Rich Horgan.

The space will be extensively renovated through the end of 2022 and into 2023, to improve the exterior, interior and parking lot of the facility. Svigal+Partners will oversee the architectural work associated with the renovations.

These renovations were partially funded by a generous grant from the Health Resources and Services Administration (HRSA), the application for which was championed by United States Senators Richard Blumenthal and Chris Murphy of Connecticut. AdvanceCT, among other nonprofit organizations and local municipalities, offered support of CRD’s proposal to HRSA.

“AdvanceCT is thrilled to welcome Cure Rare Disease to Connecticut,” said Tim Miller, Director of BD, Life Sciences, at AdvanceCT. “As one of our newest entrants to the CT life science ecosystem, CRD is making transformative progress in rare disease R&D - in addition to supporting growth for early-stage companies at their facility. We look forward to supporting them through their development.”

For leasing inquiries, please reach out to Jeff Dow at Dow Realty Co., at 203-776-0000.

ABOUT CURE RARE DISEASE

Cure Rare Disease, a 501(c)(3) nonprofit biotechnology company based in Boston, is transforming possibilities for people with rare diseases by developing advanced therapeutics in time to save lives. Through a collaborative community of forward-thinking families, patients, scientists and supporters, Cure Rare Disease has enabled an ecosystem of innovation and discovery to overcome the obstacles inherent in existing models of medicine and to expedite life-saving genetic technologies from research to the clinic. Learn more at www.cureraredisease.org.